JP2010540649A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010540649A5 JP2010540649A5 JP2010528066A JP2010528066A JP2010540649A5 JP 2010540649 A5 JP2010540649 A5 JP 2010540649A5 JP 2010528066 A JP2010528066 A JP 2010528066A JP 2010528066 A JP2010528066 A JP 2010528066A JP 2010540649 A5 JP2010540649 A5 JP 2010540649A5
- Authority
- JP
- Japan
- Prior art keywords
- aliphatic
- pharmaceutically acceptable
- acceptable salt
- treating
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 33
- 150000003839 salts Chemical class 0.000 claims description 26
- 125000001931 aliphatic group Chemical group 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 150000002431 hydrogen Chemical class 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 4
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000003981 vehicle Substances 0.000 claims description 3
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims description 2
- 208000019838 Blood disease Diseases 0.000 claims description 2
- 208000020084 Bone disease Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 claims description 2
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 230000001028 anti-proliverative effect Effects 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 150000001721 carbon Chemical group 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 230000001066 destructive effect Effects 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 208000014951 hematologic disease Diseases 0.000 claims description 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 229940121354 immunomodulator Drugs 0.000 claims description 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000037819 metastatic cancer Diseases 0.000 claims description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 2
- 239000003900 neurotrophic factor Substances 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97730507P | 2007-10-03 | 2007-10-03 | |
| PCT/US2008/078239 WO2009045992A2 (en) | 2007-10-03 | 2008-09-30 | C-met protein kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010540649A JP2010540649A (ja) | 2010-12-24 |
| JP2010540649A5 true JP2010540649A5 (OSRAM) | 2012-10-18 |
Family
ID=40512401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010528066A Pending JP2010540649A (ja) | 2007-10-03 | 2008-09-30 | ｃ−ＭＥＴタンパク質の阻害剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8481524B2 (OSRAM) |
| EP (1) | EP2205589B1 (OSRAM) |
| JP (1) | JP2010540649A (OSRAM) |
| CN (1) | CN101990538A (OSRAM) |
| AT (1) | ATE502935T1 (OSRAM) |
| AU (1) | AU2008308900A1 (OSRAM) |
| CA (1) | CA2701124A1 (OSRAM) |
| DE (1) | DE602008005786D1 (OSRAM) |
| ES (1) | ES2361650T3 (OSRAM) |
| MX (1) | MX2010003563A (OSRAM) |
| NZ (1) | NZ584311A (OSRAM) |
| WO (1) | WO2009045992A2 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009307770A1 (en) * | 2008-10-21 | 2010-04-29 | Vertex Pharmaceuticals Incorporated | C-Met protein kinase inhibitors |
| PL2521450T3 (pl) | 2010-01-07 | 2015-07-31 | Du Pont | Grzybobójcze związki heterocykliczne |
| US20130315895A1 (en) | 2010-07-01 | 2013-11-28 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
| KR101716993B1 (ko) | 2012-12-25 | 2017-03-15 | 닛뽕소다 가부시키가이샤 | 할로겐화 아닐린 및 그 제조 방법 |
| CN103242216A (zh) * | 2013-05-07 | 2013-08-14 | 兰州梦唐精细化工有限公司 | N- Boc -六氢-5-氧代环戊[C]并吡咯的合成方法 |
| US9896436B2 (en) | 2014-09-16 | 2018-02-20 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| AU2015317904A1 (en) | 2014-09-16 | 2017-04-06 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| ES2764299T3 (es) | 2014-12-09 | 2020-06-02 | Inst Nat Sante Rech Med | Anticuerpos monoclonales humanos contra AXL |
| WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007506763A (ja) * | 2003-09-24 | 2007-03-22 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用なイミダゾール組成物 |
| US7169781B2 (en) * | 2003-10-17 | 2007-01-30 | Hoffmann-La Roche Inc. | Imidazole derivatives and their use as pharmaceutical agents |
| WO2007111904A2 (en) * | 2006-03-22 | 2007-10-04 | Vertex Pharmaceuticals Incorporated | C-met protein kinase inhibitors for the treatment of proliferative disorders |
-
2008
- 2008-09-30 WO PCT/US2008/078239 patent/WO2009045992A2/en not_active Ceased
- 2008-09-30 DE DE602008005786T patent/DE602008005786D1/de active Active
- 2008-09-30 EP EP08835773A patent/EP2205589B1/en not_active Not-in-force
- 2008-09-30 NZ NZ584311A patent/NZ584311A/en not_active IP Right Cessation
- 2008-09-30 CN CN2008801170093A patent/CN101990538A/zh active Pending
- 2008-09-30 AT AT08835773T patent/ATE502935T1/de not_active IP Right Cessation
- 2008-09-30 JP JP2010528066A patent/JP2010540649A/ja active Pending
- 2008-09-30 ES ES08835773T patent/ES2361650T3/es active Active
- 2008-09-30 CA CA2701124A patent/CA2701124A1/en not_active Abandoned
- 2008-09-30 MX MX2010003563A patent/MX2010003563A/es active IP Right Grant
- 2008-09-30 AU AU2008308900A patent/AU2008308900A1/en not_active Abandoned
-
2010
- 2010-03-31 US US12/751,016 patent/US8481524B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010540649A5 (OSRAM) | ||
| US12391642B2 (en) | Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors | |
| US12077506B2 (en) | Indane derivatives as hypoxia inducible factor-2(α) inhibitors | |
| JP6664385B2 (ja) | Ｂｕｂ１阻害薬としてのベンジル置換インダゾール類 | |
| JP5461189B2 (ja) | キナーゼ活性の阻害剤 | |
| JP2012506381A5 (OSRAM) | ||
| JP2014525464A (ja) | 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途 | |
| JP2016526540A5 (OSRAM) | ||
| JP2018531921A (ja) | Ｂ型肝炎ウイルスコアタンパク質モジュレーター | |
| US12171741B2 (en) | 2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors | |
| JP2014521688A5 (OSRAM) | ||
| EP2960234A1 (en) | Trk-INHIBITING COMPOUND | |
| JP2005524631A5 (OSRAM) | ||
| JP2015508092A5 (OSRAM) | ||
| EA201070783A1 (ru) | 1,2,4-оксадизольные соединения для лечения аутоиммунных заболеваний | |
| JP2016508145A5 (OSRAM) | ||
| ES2945062T3 (es) | Derivados de ácido barbitúrico novedosos, su preparación y uso de los mismos como inhibidores de la transmigración de leucocitos y para el tratamiento de enfermedades inflamatorias, enfermedades autoinmunitarias y cáncer | |
| JP2017523141A5 (OSRAM) | ||
| CN111356687A (zh) | 含嘧啶的三取代咪唑类化合物及其应用 | |
| TW201406759A (zh) | Ｖｅｇｆｒ－３抑制劑於治療肝細胞癌之用途 | |
| US20240309031A1 (en) | Base-Modified Cytidine Nucleotides for Leukemia Therapy | |
| JP2016505049A5 (OSRAM) | ||
| WO2019245444A1 (en) | Base-modified cytidine nucleotides for leukemia therapy | |
| HK1236531A1 (en) | Benzimidazol-2-amines as midh1 inhibitors | |
| OA19743A (en) | Use of VEGFR-3 inhibitors for treating hepatocellular carcinoma. |